Prevención y tratamiento de la hipertensión arterial sistémica en el paciente con enfermedad arterial coronaria

Mendoza-González, Celso; Rosas, Martín; Estrada, Catalina; Lorenzo, José Antonio; Méndez, Arturo; Martínez-Reding, Jesús; Martínez-Sánchez, Carlos; Pastelín, Gustavo; Férez-Santander, Sergio Mario; Attie, Fause.
Arch. cardiol. Méx ; 78(supl.2): S2-58-S2-73, abr.-jun. 2008.
Artigo em Espanhol | LILACS | ID: lil-566672

Documentos relacionados

  1. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
  2. Personalized Treatment of Patients With Primary Aldosteronism.
  3. Novel mechanisms of salt-sensitive hypertension.
  4. Blocking aldosterone or its receptor-what is the difference?
  5. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
  6. [Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].
  7. Early Implementation of Aldosterone-Targeted Therapy in Patients With Hypertension.
  8. Mineralocorticoids: the secret of muscle reflex dysfunction in hypertension?
  9. Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study.
  10. Pharmacotherapy of resistant arterial hypertension.